Biotech Firm with Promising Treatment for Peripheral Nerve Damage Solicits Input from PFS Patients
PFS Foundation
The Post-Finasteride Syndrome Foundation2024-09-16
Summary (paraphrased)
Foundation news report on San Diego biotech WinSanTor, which launched a survey of PFS and PSSD patients with sexual sensory disorders as it explores expanding its topical nerve-regenerating drug pirenzepine 4% (WST-057) — developed for diabetic peripheral neuropathy — toward genital numbness. The company notes the drug could reach patients via the FDA's Expanded Access (compassionate use) pathway under its Fast Track designation. The post also cites the Milano Project's investigation of peripheral-nerve morphology in a PFS model.
Why it’s in the corpus
Genital anesthesia is a hallmark PFS/PSSD symptom framed here as peripheral nerve damage; tracks a potential repurposed therapy, a patient survey data source, and overlaps with Powers-community discussion of numbness mechanisms.